Premium
Biotechnology drugs and managed care formularies: Policies, practices, concerns
Author(s) -
Sapienza Alice M.,
Cassell Christine,
Bullock Marie
Publication year - 1998
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/(sici)1098-2299(199803)43:3<156::aid-ddr5>3.0.co;2-i
Subject(s) - formulary , sophistication , microbiology and biotechnology , business , managed care , medicine , pharmacology , health care , biology , political science , social science , sociology , law
This article describes the results of a survey of formulary managers regarding policies and practices relevant to biotechnology medicines. The objectives of the survey were to 1) classify major strategies for controlling current expenditures on biotechnology drugs within managed care plans, 2) categorize their future strategies, and 3) identify the perceived effectiveness of strategies currently in use. Results from the survey suggest that the evolving sophistication of formulary management is a major factor that must be taken into consideration early in clinical research efforts, as well as in the design of clinical trials. Drug Dev. Res. 43:156–163, 1998. © 1998 Wiley‐Liss, Inc.